human clinical trials
Big Data and AI Can Guide Cannabis Medicine
In order for cannabis medicine to make the big leap to mainstream acceptance, a few things likely have to take place. Doctors, not just cannabis providers, need to become more comfortable discussing and prescribing the plant. Regulations need to become more homogenous and universal, like the pharmaceutical industry. Pharma companies need to advance more cannabis-derived […]
Trial will take place at major U.S. centers and examine the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease (CVD) Oakville, Ontario–(Newsfile Corp. – September 25, 2020) – Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (“Cardiol” or the “Company“), a clinical-stage biotechnology company focused […]
Ehave, Inc. Appoints Dr. Mark Braunstein as Chief Psychedelic Officer
Dr. Braunstein is recognized worldwide in Psychedelic Psychiatry, which entails treating psychiatric disorders with psychedelics Dr. Braunstein is a renowned expert on psychedelic therapy and addiction. As a pioneer in psychedelic medicine research, he specializes in the treatment of ADHD, depression, anxiety, bipolar disorder, substance abuse, oppositional defiance, personality disorders, and treatment resistance. He has […]
Psychedelics: Investing in the Perfect BrainStorm
Psychedelics are rapidly becoming both a mainstream treatment option and investment opportunity. With growing interest among researchers, forward-thinking companies are starting to build a presence in the space. In this article, we will take a look at the growing body of therapeutic evidence for psychedelics. How decriminalization is gaining ground, and how Ehave Inc. (OTC: […]
More Companies Lining Up to Get Their Hands on Lexaria’s DehydraTECH™ Platform
When you’ve got something great, it may take a little bit of time for people to learn about it, but once word starts getting around, it can yield a windfall of interest. That’s the case with Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) and its DehydraTECH™ technology that enhances qualities and uptake of all sorts […]
Sublime’s Stellar Team Sets It Apart in Cannabis Edibles
Sublime Canna, an award-winning cannabis manufacturing company located in California, has made headlines for the launch of Dosies, a cannabis-infused mint that’s both designed to be a throwback to the days of Tic Tacs and a way to consistently microdose specific cannabinoids. Unlike many edibles manufacturers, novelty isn’t the company’s only differentiating factor. The experienced […]
Pascal Biosciences Announces Formation of Clinical Advisory Board
Preeminent Neuro-Oncology Experts to Guide PAS-403 Development Efforts VANCOUVER, British Columbia and SEATTLE, May 08, 2019 (GLOBE NEWSWIRE) — Pascal Biosciences Inc. (TSX.V:PAS)(“Pascal” or the “Company”), a drug discovery and development company, today announced it has formed a clinical advisory board (“CAB”) of preeminent neuro-oncology experts to guide its PAS-403 therapeutic program. PAS-403 is Pascal’s clinical […]
FSD Pharma Doubles Down on Endocannabinoid-based Pain Management
Chronic pain is a widespread condition affecting about one-third of the American population and billions of other people around the world. Despite their widely known dangers, opioids quickly became one of the most prescribed and profitable classes of drugs in the world. The ensuing opioid crisis has made overdoses a leading cause of non-disease deaths […]
Supreme Cannabis Continues To Achieve Milestones in 2019
The Canadian cannabis industry is projected to reach C$22.6 billion over the coming years, according to Deloitte, driven by the legalization of adult-use cannabis last year and the upcoming legalization of edibles later this year. While many companies have focused on scaling up their production capacity at any cost, investors may want to shift focus […]
Interview with Gabriella’s Kitchen CEO Margot Micallef
CFN Media recently sat down with Gabriella’s Kitchen (CSE: GABY) (OTCBB:GABLF) CEO Margot Micallef to discuss the global implications of Gaby’s innovative products. New beginnings Gabriella’s Kitchen is a cannabis wellness company founded in health and nutrition. Spurred by a dire cancer prognosis, sisters Gabriella and Margot sought a healthier lifestyle that might prolong Gabriella’s life. […]
Authors Leveraged Aleafia’s 10 Million Point Medical Cannabis Dataset TORONTO, Jan. 25, 2019 (GLOBE NEWSWIRE) — Aleafia Health Inc. (TSXV: ALEF, OTC: ALEAF, FRA: ARAH) (“Aleafia Health” or the “Company”), announces today what it believes to be the first study reporting reduced benzodiazepine use among patients initiated and monitored on medical cannabis. Benzodiazepines, a class […]
Pascal Biosciences Provides Year-End Investor Update and Reviews Upcoming Milestones
– 2018 pipeline expansion includes lead cannabinoid-based cancer therapeutic – Clinical trial in glioblastoma to begin in 2019 VANCOUVER, British Columbia and SEATTLE, Dec. 20, 2018 (GLOBE NEWSWIRE) — Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced a year-end review of accomplishments during 2018 and insight into plans […]
Creso Pharma Brings Together Cannabis Experts Across Several Verticals
The due diligence process looks very different for small-cap versus large-cap stocks. When analyzing large-cap companies, investors pay closest attention to financial statements and valuation ratios to extrapolate growth rates and apply multiples. Small-cap stocks tend to be earlier stage companies without an established earnings track record, which means that investors must consider the management […]
Canntab Partners with Leading Surgeon to Conduct Pain Management Trial
The opioid industry is expected to generate nearly $20 billion in annual revenue by 2020, but the addictive nature of the drug has doctors and patients increasingly concerned. With the legalization of cannabis across Canada and many U.S. states, there’s an opportunity to replace dangerous opioids with efficacious cannabinoids to treat chronic and acute pain. […]
VANCOUVER, BRITISH COLUMBIA, and SEATTLE, WASHINGTON, November 28, 2018 – Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced the strengthening of its leadership team with the appointments of seasoned executives in therapeutic and business development. These include Kevin M. Egan, MBA, Vice President Business Development, Thomas Deckwerth, […]
Lexaria Targets Cannabinoids, Tobacco, Hemp, and Pharma Markets with New Subsidiaries
The cannabis industry is projected to generation hundreds of billions of dollars of revenue over the coming years, driven by the legalization of medical and recreational cannabis across North America. While many investors are focused on cultivation or dispensary operations, drug delivery technologies may represent an even bigger opportunity. These companies have an opportunity to […]
Gabriella’s Kitchen Is Redefining The Cannabis Health and Wellness Industry
Gabriella’s Kitchen (CSE: GABY), the award-winning consumer packaged goods company whose array of super-nutritional foods are currently sold in more than 3,400 stores across North America, is launching a revolutionary new line of cannabis infused nutritional edibles. The expansion as well as a number of announced acquisitions has positioned the company on the cutting edge […]
CALGARY and SANTA ROSA, CA, Nov. 9, 2018 /CNW/ – Gabriella’s Kitchen Inc. (the “Company” or “GABY”) (CSE: GABY) today provided comments to shareholders on recent changes in United States cannabis regulations, plus other national and international developments in the cannabis sector. GABY commented to shareholders today on recent draft regulations that have been released by the […]
CFN Media’s Exclusive Interview with Pascal Biosciences
The cannabis industry is projected to reach $75 billion by 2030, according to Cowen & Co., driven by the legalization of medical and recreational cannabis across a growing number of states. While many investors are familiar with cultivators and dispensaries, there could be an even greater opportunity on the medical side of the industry. Cannabinoids […]
– Program Developed in Lab of Renowned Cannabis Researcher Dr. Nephi Stella – Lead Candidate for Glioblastoma to Begin Clinical Testing in 2019 VANCOUVER, BRITISH COLUMBIA, and SEATTLE, WASHINGTON, October 30, 2018 – Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced that the Company has entered into […]
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Matt Hawkins is the founder and managing principal of Cresco Capital Partners, LLC (“Cresco”), a private equity firm focused specifically on investing in the legalized cannabis industry. Since its inception in the summer of 2015, Cresco has made 14 investments out of its first fund and is currently raising this fund, Fund II. Prior to the […]
Matthew Nordgren is an ambitious executive, dedicated philanthropist, and accomplished athlete who brings a unique passion to creating strategic alliances. He has breadth and depth of experience in finance, corporate development, and capital sourcing, as well as in building highly motivated teams of skilled professionals. In 2005, Mr. Nordgren received his education at the University […]
CaniBrands is a next-generation wellness products company that specializes in manufacturing innovative CBD (Cannabidiol) formulations for sports recovery and active living. CaniBrands products are trusted by professional athletes and backed by science. The company has a wide selection of products for sports recovery, energy, focus, pain and sleep. Along with sublingual oils, balms and creams, […]
Delta 9’s wholly-owned subsidiary, Delta 9 Bio-Tech Inc., is a licensed producer of medical marijuana pursuant to the ACMPR and operates an 80,000 square foot production facility in Winnipeg, Manitoba, Canada . Delta 9’s shares trade on the TSX Venture Exchange under the symbol “NINE”.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
